Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of November: Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website. For more information about this conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Pharming's Investor Relations team at investor@

Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Third quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarter 2023Overall

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration:Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BId118ac68d9

Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS  Clinical trial being conducted at the National Institutes of Health (NIH) Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the start of a Phase II, proof of concept, clinical trial evaluating leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes. The clinical t

For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Leniolisib, an oral, selective PI3Kδ inhibitor, is the first treatment approved in the U.K. specifically fo

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website.H.C. Wainwright 26th Annual Global Investment Conference, New York, September 9-11Sijmen de Vries, Chief Executive Officer, will

Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)Overall cash and marketable securities declined to US$161.8 million at the end of the second quarter 2024 from US$203.5 million a

Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BI9232

Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website. Oppenheimer Novel Targets in Immunology Summit, New York, USA, June 24, 2024Anurag Relan, Chief Medical Officer, will participate in the panel "Taking the Inflammation out of I&I - Novel Approaches for Inf

Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the adoption of the updated Remuneration Policy for members of the Board of Directors (agenda item 3), the authorization for the Board of Directors to issue shares and/or options (agenda item 5) and the authorizatio

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:UPS) for $1.025 billion in cash. As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO. RXO shares jumped 13.3% to $22.90 in pre-market trading. Here are some big s

U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Shoals Technologies Group, Inc. (NASDAQ:SHLS) rose sharply during Monday's session after the company authorized a share repurchase program of up to $150 million and entered into a $25 million accelerated share repurchase agreement with Jefferies. Shoals Technologies Group shares climbed 10% to $7.49 on Tuesday. Here are some other big stocks recording gains in today’s session. Calavo Growers, Inc. (NASDAQ:CVGW) shares jumped 14.1% to $28.50 after the company reported second-quarter financial results. Olaplex Holdings, Inc. (NASDAQ:OLPX) jumped 8.9% to $1.8350. Corbus Pharmaceutic

Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of The J. M. Smucker Company (NYSE:SJM) rose sharply during Thursday’s session following upbeat quarterly earnings. The company reported a fourth-quarter FY24 sales decline of 1.3% year-on-year to $2.21 billion, missing the analyst consensus estimate of $2.24 billion. Adjusted EPS of $2.66 beat the analyst consensus estimate of $2.33, according to data from Benzinga Pro. Smucker shares climbed 6.2% to $117.16 on Thursday. Here are some other big stocks recording gains in today’s session. Latam Logistic Properties, S.A. (NYSE:LPA) shares surged 99.2% to $63.01 after dipping aroun

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. Shares of Bath & Body Works Inc (NYSE:BBWI) fell in today's pre-market trading after the company reported first-quarter earnings. Bath & Body Works posted adjusted earnings of 38 cents per share, beating market estimates of 32 cents per share. The company's quarterly sales came in at $1.38 billion versus expectations of $1.36 billion, according to data from Benzinga Pro. Bath & Body Works shares dipped 7.4% to $48.00 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Lufax Holding Ltd – ADR (NYSE:LU) shares dipped 51.1% to

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Modine Manufacturing Company (NYSE:MOD) shares fell sharply in today’s pre-market trading following mixed fourth-quarter results. Modine Manufacturing posted adjusted earnings of 77 cents per share, versus market estimates of 76 cents per share. The company's quarterly sales came in at $603.50 million compared to expectations of $605.36 million, according to data from Benzinga Pro. Modine Manufacturing shares tumbled 8.8% to $92.50 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. LifeStance Health Group, Inc.

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 290 percent. This is unchanged from the same period last year. The company reported quarterly sales of $55.586 million which missed the analyst consensus estimate of $68.425 million by 18.76 percent. This is a 30.66 percent increase over sales of $42.541 million the same period last year.

Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market

Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).   Leniolisib, marketed under the brand name Joenja® in the U.S., received approval from the US Food and Drug Administration (FDA) for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. Pharming plans to include data from this 4–11-year-old trial in regulatory filings worldwide for the